palmitoylethanolamide.com.au
HomeResearchAmira 2022

Palmitoylethanolamide Mitigates Paclitaxel Toxicity in Primary Dorsal Root Ganglion Neurons

Amira Elfarnawany, Faramarz Dehghani. Biomolecules. 2022 Dec 14;12(12):1873.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Primary dorsal root ganglion (DRG) neurons isolated from 6- to 8-week-old Wistar rats
Dose used in the study
Paclitaxel (0.01-10 micromolar) or palmitoylethanolamide (0.1-10 micromolar) alone or combined, applied to cultured neurons
Duration
Assessed at 24, 48 and 72 hours after treatment
What was measured
Cell viability (MTT assay), neurite length and soma size of dorsal root ganglion neurons

What the authors reported

This laboratory study found:

  • Paclitaxel reduced cell viability at 72 hours and reduced neurite length at nearly all time points while increasing soma size.
  • Adding palmitoylethanolamide reduced these paclitaxel effects.
  • Palmitoylethanolamide alone increased neuron viability at all concentrations tested, improved neurite outgrowth, and decreased soma size at some time points.

Limits of this study

A cell-culture study using isolated rat neurons; it cannot show effect in people or animals with chemotherapy-induced neuropathy. The authors declare no conflict of interest.

Source

PubMed 36551301 · doi:10.3390/biom12121873

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.